Intravitreal conbercept injection for neovascular age-related macular degeneration
AIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept mont...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2019-02-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2019/2/20190211.pdf |
id |
doaj-8ff1c71e84f040ffbf68574d94611e1c |
---|---|
record_format |
Article |
spelling |
doaj-8ff1c71e84f040ffbf68574d94611e1c2020-11-24T21:52:12ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982019-02-0112225225710.18240/ijo.2019.02.11Intravitreal conbercept injection for neovascular age-related macular degenerationBing-Hui Wu0Bing Wang1Hui-Qin Wu2Qin Chang3Hui-Qin Lu4Department of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710001, Shaanxi Province, ChinaDepartment of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710001, Shaanxi Province, ChinaDepartment of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710001, Shaanxi Province, ChinaDepartment of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710001, Shaanxi Province, ChinaDepartment of Ophthalmology, Xi’an No.1 Hospital, Xi’an 710001, Shaanxi Province, ChinaAIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 consecutive months, and then pro re nata treatment was performed. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and after treatments. Minimum follow-up time was 12mo. SPSS 22.0 statistical software was used for statistical analysis. RESULTS: The mean BCVA and CMT of 66 eyes (63 patients) were 1.11±0.60, 533.20±219.95 µm at baseline, and were 0.68±0.38, 310.28±125.60 µm at 3mo. No subjects were lost during the first three months, the improvements were all significantly (P<0.05). During the whole follow-up time of 12mo, 15 subjects (18 eyes) were lost. The mean BCVA and CMT of the rest 48 eyes with the follow-up time at least 1y were 0.83±0.46 and 547.59±196.77 µm at baseline, after 3mo and 12mo of conbercept injections became 0.55±0.41, 318.24±141.29 µm and 0.55±0.51, 333.87±173.25 µm. The differences were significant (P<0.05). No serious complications were observed. CONCLUSION: Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with neovascular AMD, no serious adverse reactions and complications are observed.http://www.ijo.cn/en_publish/2019/2/20190211.pdfage-related macular degenerationintravitreal injectionconbercept |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bing-Hui Wu Bing Wang Hui-Qin Wu Qin Chang Hui-Qin Lu |
spellingShingle |
Bing-Hui Wu Bing Wang Hui-Qin Wu Qin Chang Hui-Qin Lu Intravitreal conbercept injection for neovascular age-related macular degeneration International Journal of Ophthalmology age-related macular degeneration intravitreal injection conbercept |
author_facet |
Bing-Hui Wu Bing Wang Hui-Qin Wu Qin Chang Hui-Qin Lu |
author_sort |
Bing-Hui Wu |
title |
Intravitreal conbercept injection for neovascular age-related macular degeneration |
title_short |
Intravitreal conbercept injection for neovascular age-related macular degeneration |
title_full |
Intravitreal conbercept injection for neovascular age-related macular degeneration |
title_fullStr |
Intravitreal conbercept injection for neovascular age-related macular degeneration |
title_full_unstemmed |
Intravitreal conbercept injection for neovascular age-related macular degeneration |
title_sort |
intravitreal conbercept injection for neovascular age-related macular degeneration |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2019-02-01 |
description |
AIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD).
METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5 mg intravitreal injections of conbercept monthly for 3 consecutive months, and then pro re nata treatment was performed. The changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before and after treatments. Minimum follow-up time was 12mo. SPSS 22.0 statistical software was used for statistical analysis.
RESULTS: The mean BCVA and CMT of 66 eyes (63 patients) were 1.11±0.60, 533.20±219.95 µm at baseline, and were 0.68±0.38, 310.28±125.60 µm at 3mo. No subjects were lost during the first three months, the improvements were all significantly (P<0.05). During the whole follow-up time of 12mo, 15 subjects (18 eyes) were lost. The mean BCVA and CMT of the rest 48 eyes with the follow-up time at least 1y were 0.83±0.46 and 547.59±196.77 µm at baseline, after 3mo and 12mo of conbercept injections became 0.55±0.41, 318.24±141.29 µm and 0.55±0.51, 333.87±173.25 µm. The differences were significant (P<0.05). No serious complications were observed.
CONCLUSION: Intravitreal injection of conbercept appears to significantly improve visual acuity and anatomical outcomes in patients with neovascular AMD, no serious adverse reactions and complications are observed. |
topic |
age-related macular degeneration intravitreal injection conbercept |
url |
http://www.ijo.cn/en_publish/2019/2/20190211.pdf |
work_keys_str_mv |
AT binghuiwu intravitrealconberceptinjectionforneovascularagerelatedmaculardegeneration AT bingwang intravitrealconberceptinjectionforneovascularagerelatedmaculardegeneration AT huiqinwu intravitrealconberceptinjectionforneovascularagerelatedmaculardegeneration AT qinchang intravitrealconberceptinjectionforneovascularagerelatedmaculardegeneration AT huiqinlu intravitrealconberceptinjectionforneovascularagerelatedmaculardegeneration |
_version_ |
1725876242698207232 |